Reason Behind The Drop in PRA Health Sciences, Inc. (NASDAQ:PRAH) Stock Price
Shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) declined -6.00% in morning trade Wednesday, soon after a contract research organization declared the pricing of the formerly declared secondary offering of shares of its common stock. Certain of the Company’s stockholders, counting an associate of, or a fund sponsored by, Kohlberg Kravis Roberts & Co. (the “Selling Stockholders”), have agreed to sell an aggregate of 10,000,000 shares of the Company’s common stock in an underwritten public offering. The shares will be offered from time to time for sale in one or more transactions on the Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The offering is predictable to close on August 14, 2017, subject to customary closing conditions.
Morgan Stanley and Wells Fargo Securities acted as the underwriters for the offering.
The stock closed its last trade at the price of $79.14, while exchanging hands with the volume of 1440292 shares contrast to its average daily volume of 429.59K shares. Trading volume is an important technical indicator a shareholder uses to confirm a trend or trend reversal. It is generally higher when the price of a security is changing, as the strength of any given price movement is measured mainly by the volume and shifts in trade volume can make observed price movements more significant. News about a company’s financial status, products, or plans, whether positive or negative, will typically result in a temporary increase in the trade volume of its stock. Higher volume for a stock is also an indicator of higher liquidity in the market. For institutional shareholders who wish to sell a large number of shares of a certain stock, lower liquidity will force them to sell the stock slowly over a longer period of time, to avoid losses because of slippage. The stock, as of recent close, has shown weekly upbeat performance of 6.160% which was maintained at 5.45% in 1-month period, and is up 43.57% in this year. The company now has a market value of $4.94B.
The stock, after recent close, is 6.29% above their SMA 50 and 4.99% from SMA20 and is 25.30% above than SMA200. 0% shares of the company were owned by institutional investors. The company has 2.640 values in price to sale ratio while price to book ratio was recorded as 6.29. It beta stands at -.
The average 12 month target price among brokers that have covered the stock in the last year is $82. Analyst mean recommendation for this stock stands at 1.5. Analyst recommendations as stated on FINVIZ are rated on a 1 to 5 scale. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The consensus recommendation is the average rating on a stock by the analyst community.
